Side effects of commonly used glaucoma medications: Comparison of tolerability, chance of discontinuation, and patient satisfaction

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 10, 2008, Pages 1485-1490

  Beckers, Henny J M ^a   Schouten, Jan S A G ^a   Webers, Carroll A B ^a   Valk, Rikkert ^a   Hendrikse, Fred ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Glaucoma; Glaucoma medication; Side effects

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BETOPTIC S; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARTEOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; GELLAN; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; METIPRANOLOL; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE; TIMOPTOL XE; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSTAGLANDINS F, SYNTHETIC; QUESTIONNAIRES; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 51649104272     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0875-7     Document Type: Article

References (19)

1. van der Valk R, Schouten JS, Webers CA, Hendrikse F, Prins MH (2006) Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication. Graefes Arch Clin Exp Ophthalmol 244:1267-1272, doi: 10.1007/s00417-005-0241-y
2. van der Valk R, Webers CA, Hendrikse F, de Vogel SC, Prins MH, Schouten JS (2007) Predicting intraocular pressure change before initiating therapy: Timolol versus latanoprost. Acta Ophthalmol Scand, doi: 10.1111/ j.1600-0420.2007.01065.x
3. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA (1997) Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 104:334-342
4. Redactie farmacotherapeutisch kompas (2005) Ophthalmologica. In: Loenen AC van (ed) Farmacotherapeutisch kompas. College voor zorgverzekeringen, koninklijke bibliotheek, den Haag
5. Camras CB, Toris CB, Tamesis RR (1999) Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging 15:377-388, doi: 10.2165/00002512-199915050-00005
6. Cantor LB (2002) An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother 3:1753-1762, doi: 10.1517/14656566.3.12.1753
7. David R (2001) Brimonidine (Alphagan): A clinical profile four years after launch. Eur J Ophthalmol 11(Suppl 2):S72-S77
8. Eisenberg DL, Toris CB, Camras CB (2002) Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv Ophthalmol 47(Suppl 1):S105-S115, doi: 10.1016/S0039-6257(02)00327-2
9. Frampton JE, Perry CM (2006) Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: A review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging 23:977-995, doi: 10.2165/ 00002512-200623120-00005
10. Herkel U, Pfeiffer N (2001) Update on topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol 12:88-93, doi 10.1097/ 00055735-200104000-00002
11. Higginbotham EJ, Diestelhorst M, Pfeiffer N, Rouland JF, Alm A (2002) The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 47(Suppl 1):S133-S140, doi: 10.1016/S0039-6257(02)00295-3
12. Hoy SM, Keam SJ, Keating GM (2006) Travoprost/timolol. Drugs Aging 23:587-597 discussion 598-589, doi: 10.2165/00002512-200623070-00005
13. Perry CM, McGavin JK, Culy CR, Ibbotson T (2003) Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs Aging 20:597-630, doi: 10.2165/00002512-200320080-00005
14. van der Valk R, Schouten JSAG, Webers CAB, Beckers HJM, van Amelsvoort LGPM, Schouten HJA et al (2005) The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries. J Glaucoma 14:239-242, doi: 10.1097/ 01.ijg.0000159121.11371.5f
15. Baudouin C (2005) Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 5:459-463, doi: 10.1097/01.all.0000183112.86181.9e
16. Yee RW (2007) The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: A review. Curr Opin Ophthalmol 18:134-139, doi: 10.1097/ICU.0b013e328089f1c8
17. Lama PJ (2002) Systemic adverse effects of beta-adrenergic blockers: An evidence-based assessment. Am J Ophthalmol 134:749-760, doi: 10.1016/ S0002-9394(02)01699-9
18. Santaella RM, Fraunfelder FW (2007) Ocular adverse effects associated with systemic medications: Recognition and management. Drugs 67:75-93, doi: 10.2165/00003495-200767010-00006
19. Labetoulle M, Frau E, Le Jeunne C (2005) Systemic adverse effects of topical ocular treatments. Presse Med 34:589-595, doi: 10.1016/ S0755-4982(05)83987-9